Pharmacovigilance update;Pharmacovigilance

Revue Medicale Suisse

Volumn 9, Issue 368, 2013, Pages 72-75

  Livio, F ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ALISKIREN; ANTIRETROVIRUS AGENT; ATOMOXETINE; BOCEPREVIR; CITALOPRAM; DABIGATRAN; FINGOLIMOD; FUSIDIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; LIVER ENZYME; ONDANSETRON; TELAPREVIR;

ACUTE PANCREATITIS; BLEEDING; BLOOD PRESSURE; BRADYCARDIA; DRUG SURVEILLANCE PROGRAM; GERIATRIC PATIENT; HEART BLOCK; HEART RATE; HUMAN; KIDNEY FAILURE; REVIEW; RHABDOMYOLYSIS;

ADRENERGIC UPTAKE INHIBITORS; AGE FACTORS; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BETA-ALANINE; CARDIOVASCULAR DISEASES; DRUG TOXICITY; FIBRINOLYTIC AGENTS; FUMARATES; HEMORRHAGE; HUMANS; PHARMACOVIGILANCE; PROPYLAMINES;

EID: 84872733189     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
2. Moore TJ, Furberg CD, Cohen MR. QuarterWatch-Monitoring FDA MedWatch reports. www.ismp.org/QuarterWatch/pdfs/2011Q4.pdf (consulté en novembre 2012).
3. * Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012;366:864-6.
4. www.compendium.ch (consulté en novembre 2012).
5. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; epub ahead of print.
6. www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON185628 (consulté en novembre 2012).
7. Girgis CM, Champion BL. Vildagliptin-induced acute pancreatitis. Endocr Pract 2011;17:e48-50.
8. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 2011;45:e22.
9. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: A review. Diabetes Metab Res Rev 2011;27:528-42.
10. Iyer SN, Drake AJ, West RL, et al. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr Pract 2012;18:e10.
11. * Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7.
12. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010;53:153-9.
13. Butler PC, Matveyenko AV, Dry A, et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: Innocent bystander or friendly fire? Diabetologia 2010;53:1-6.
14. WHO Pharmaceuticals Newsletter 2011;5:8.
15. Dromer C, Vedrenne C, Billey T, et al. Rhabdomyolysis due to simvastatin. Rev Rhum Mal Osteoartic 1992;59:281-3.
16. Kearney S, Carr AS, McConville J, et al. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ 2012;345:e6562.
17. Khaliq Y, Gallicano K, Leger R, et al. A drug interaction between fusidic acid and a combination of ritonavir and saquinavir. Br J Clin Pharmacol 2000;50:82-3.
18. www.fda.gov/Drugs/DrugSafety/ucm291119.htm (consulté en novembre 2012).
19. ** www.hiv-druginteractions.org/ (consulté en novembre 2012).
20. Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: A close look at the role for direct-acting antivirals. Gastroenterology 2012;142:1324-34.
21. www.fda.gov/Drugs/DrugSafety/ucm297391.htm (consulté en novembre 2012).
22. www.mhra.gov.uk/home/groups/dsu/documents/publication/con180638.pdf (consulté en novembre 2012).
23. www.mhra.gov.uk/home/groups/dsu/documents/publication/con140708.pdf (consulté en novembre 2012).
24. ** Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat 2009;5:563-76.
25. www.mhra.gov.uk/home/groups/dsu/documents/publication/con199577.pdf (consulté en novembre 2012).
26. http://hc-sc.gc.ca/dhp-mps/alt-formats/pdf/medeff/advisories-avis/public/ 2012/gilenya-pc-cp-fra.pdf (consulté en novembre 2012).